CLOs on the Move

Volition

www.volition.com

 
Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.volition.com
  • 13215 Bee Cave Parkway Galleria Oaks B, Suite 125
    Austin, TX USA 78738
  • Phone: 646.650.1351

Executives

Name Title Contact Details

Similar Companies

Insightra Medical

Insightra Medical is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Blueberry Medical

Blueberry Pediatrics is a company that provides 24/7 on-demand pediatric care through a smartphone app, with $0 visits and home medical devices available.

API Healthcare Corporation

API Healthcare Corporation is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Hartford, WI. To find more information about API Healthcare Corporation, please visit www.apihealthcare.com

Family Health Care Clinic

Family Health Care Clinic is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Prescott Valley, AZ. To find more information about Family Health Care Clinic, please visit www.familyhealthcareclinic.com

Orbus Therapeutics

Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.